RIBOMIC Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies called the RiboART System. RIBOMIC has been promoting the pharmaceutical discovery program in collaboration with Otsuka Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., The University of Tokyo, and some...Read More
Aptamer Solutions Ltd: Continued success and growth has enabled Aptamer Group to restructure its Scientific Operations team. Increasing interest in the development of aptamers against small molecule targets has led to the formation of a dedicated scientific team. This is in addition to the existing team focused on aptamer generation against larger targets (proteins, viruses,...Read More
We are delighted to announce that Professor Günter Mayer will chair Aptamers 2019. Professor Mayer is the Professor of Chemical Biology at Life and Medical Sciences Institute (LIMES), Bonn University, Germany, and heads an international team of researchers investigating the use of aptamer technology in understanding biological phenomena and developing nucleic acids as drugs or drug targets...Read More
Membership is currently free and is open to researchers from academia and industry with interest in the field of aptamers. Please complete the registration form to apply for membership. Membership Categories Industry Academic – Lecturer/Professor/Group Leader Academic – Post-doctoral Researcher Academic – Student Become an INSOAP member to access: Job listings in the field of aptamers Occasional...Read More
Aptamers – The official journal of the International Society on Aptamers – will consider and publish peer-reviewed studies on all aspects of aptamer research. The journal is now accepting manuscripts. Publish Free: There is no Article Processing Fee until 31 July 2018, as long as the submitted manuscripts are prepared within the recommended size limits and according to...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.